欧洲药品管理局-话题@MedSci

#欧洲药品管理局#

58篇内容 | 1321人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1425464, encodeId=1caf1425464b7, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Acceleron的TGF-β配体陷阱Sotatercept治疗肺动脉高压，获得欧洲药品管理局的优先药品（PRIME）称号, objectType=article, longId=193600, objectId=d0bf193600be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0bf193600be, replyNumber=0, likeNumber=16, createdTime=2020-05-08, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0bf193600be, moduleTitle=Acceleron的TGF-β配体陷阱Sotatercept治疗肺动脉高压，获得欧洲药品管理局的优先药品（PRIME）称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0bf193600be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425463, encodeId=9c5f14254637b, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Medivir的MIV-818治疗肝细胞癌，获得欧洲药品管理局对其孤儿药指定的积极评价, objectType=article, longId=193388, objectId=0f7919338822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f7919338822, replyNumber=0, likeNumber=41, createdTime=2020-05-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f7919338822, moduleTitle=Medivir的MIV-818治疗肝细胞癌，获得欧洲药品管理局对其孤儿药指定的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f7919338822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425462, encodeId=475a142546225, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, objectType=article, longId=193381, objectId=964219338183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=964219338183, replyNumber=0, likeNumber=45, createdTime=2020-05-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=964219338183, moduleTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=964219338183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425461, encodeId=46d91425461d8, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局：授予MB-107慢病毒基因疗法治疗X连锁严重综合免疫缺陷病的先进疗法分类, objectType=article, longId=192703, objectId=981b192e0390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981b192e0390, replyNumber=0, likeNumber=22, createdTime=2020-04-23, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981b192e0390, moduleTitle=欧洲药品管理局：授予MB-107慢病毒基因疗法治疗X连锁严重综合免疫缺陷病的先进疗法分类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=981b192e0390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425460, encodeId=43a3142546029, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, objectType=article, longId=191467, objectId=538b19146ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538b19146ee0, replyNumber=0, likeNumber=26, createdTime=2020-04-06, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538b19146ee0, moduleTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538b19146ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425459, encodeId=df69142545950, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=基因疗法抗击卵巢癌：欧洲药品管理局授予GEN-1孤儿药认定, objectType=article, longId=190731, objectId=6e06190e31bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e06190e31bf, replyNumber=0, likeNumber=39, createdTime=2020-03-26, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e06190e31bf, moduleTitle=基因疗法抗击卵巢癌：欧洲药品管理局授予GEN-1孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e06190e31bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425458, encodeId=4d8514254580d, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Myovant Sciences向欧洲药品管理局提交了Relugolix联合片剂治疗子宫肌瘤的上市许可申请, objectType=article, longId=189703, objectId=49a0189e030c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49a0189e030c, replyNumber=0, likeNumber=42, createdTime=2020-03-12, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49a0189e030c, moduleTitle=Myovant Sciences向欧洲药品管理局提交了Relugolix联合片剂治疗子宫肌瘤的上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49a0189e030c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425457, encodeId=2fde142545eea, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号, objectType=article, longId=189502, objectId=3dc618950238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc618950238, replyNumber=0, likeNumber=21, createdTime=2020-03-08, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc618950238, moduleTitle=Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc618950238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425456, encodeId=c756142545694, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市, objectType=article, longId=189500, objectId=7a3e18950020, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a3e18950020, replyNumber=0, likeNumber=38, createdTime=2020-03-08, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a3e18950020, moduleTitle=欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a3e18950020)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425455, encodeId=b22314254553e, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘, objectType=article, longId=189156, objectId=227218915615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=227218915615, replyNumber=0, likeNumber=31, createdTime=2020-03-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=227218915615, moduleTitle=欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=227218915615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425454, encodeId=11dc1425454d9, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, objectType=article, longId=187393, objectId=e5f218e3936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5f218e3936c, replyNumber=0, likeNumber=41, createdTime=2020-02-05, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5f218e3936c, moduleTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5f218e3936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425453, encodeId=02f5142545375, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, objectType=article, longId=187289, objectId=33a518e289cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a518e289cb, replyNumber=0, likeNumber=43, createdTime=2020-02-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a518e289cb, moduleTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33a518e289cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425452, encodeId=78e5142545207, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, objectType=article, longId=187285, objectId=d73e18e28514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d73e18e28514, replyNumber=0, likeNumber=38, createdTime=2020-02-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d73e18e28514, moduleTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d73e18e28514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425451, encodeId=55c41425451a9, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, objectType=article, longId=187284, objectId=4eb418e284e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb418e284e5, replyNumber=0, likeNumber=43, createdTime=2020-02-04, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb418e284e5, moduleTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb418e284e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425450, encodeId=98e01425450f3, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, objectType=article, longId=187241, objectId=618618e241e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618618e241e2, replyNumber=0, likeNumber=26, createdTime=2020-02-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618618e241e2, moduleTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618618e241e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425449, encodeId=de491425449a9, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格, objectType=article, longId=187027, objectId=74ee18e02744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ee18e02744, replyNumber=0, likeNumber=34, createdTime=2020-02-01, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ee18e02744, moduleTitle=欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ee18e02744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425448, encodeId=d99114254489c, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, objectType=article, longId=185054, objectId=f497185054c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f497185054c2, replyNumber=0, likeNumber=16, createdTime=2019-12-23, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f497185054c2, moduleTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f497185054c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425447, encodeId=190a142544eda, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症, objectType=article, longId=183190, objectId=6e8f18319058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e8f18319058, replyNumber=0, likeNumber=39, createdTime=2019-11-20, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e8f18319058, moduleTitle=欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e8f18319058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425446, encodeId=073f142544602, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, objectType=article, longId=181828, objectId=a684181828c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a684181828c3, replyNumber=0, likeNumber=39, createdTime=2019-10-25, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a684181828c3, moduleTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a684181828c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425445, encodeId=ef691425445f6, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐, objectType=article, longId=181603, objectId=223b18160372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=223b18160372, replyNumber=0, likeNumber=35, createdTime=2019-10-21, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=223b18160372, moduleTitle=安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=223b18160372)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲药品管理局

2020-05-29

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Acceleron的TGF-β配体陷阱Sotatercept治疗肺动脉高压，获得欧洲药品管理局的优先药品（PRIME）称号

2020-05-08

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Medivir的MIV-818治疗肝细胞癌，获得欧洲药品管理局对其孤儿药指定的积极评价

2020-05-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘

2020-05-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局：授予MB-107慢病毒基因疗法治疗X连锁严重综合免疫缺陷病的先进疗法分类

2020-04-23

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19

2020-04-06

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

基因疗法抗击卵巢癌：欧洲药品管理局授予GEN-1孤儿药认定

2020-03-26

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Myovant Sciences向欧洲药品管理局提交了Relugolix联合片剂治疗子宫肌瘤的上市许可申请

2020-03-12

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号

2020-03-08

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市

2020-03-08

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局接受葛兰素史克的申请，寻求将Trelegy Ellipta三联吸入式疗法用于治疗哮喘

2020-03-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请

2020-02-05

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病

2020-02-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤

2020-02-04

医者仁心 (审核中...)

前往app查看评论内容

#欧洲药品管理局#

强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌

2020-02-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请

2020-02-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格

2020-02-01

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定

2019-12-23

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症

2019-11-20

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎

2019-10-25

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐

2019-10-21

科室
- - 订阅+
  - 更多科室
工具
服务